`Stephen B. Kahl, Ph.D.Stephen B. Kahl, Ph.D.
`
`April 07, 2016April 07, 2016
`
`·
`
`·1· · · ·IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
`
`·2· · · · · ·BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`·3· _________________________________
`· · · · · · · · · · · · · · · · · · ·)
`·4· COALITION FOR AFFORDABLE DRUGS· ·)
`· · X LLC,,· · · · · · · · · · · · · )
`·5· · · · · · · · · · · · · · · · · ·)
`· · · · · · · · · ·Petitioner,· · · ·)
`·6· · · · · · · · · · · · · · · · · ·)
`· · vs.· · · · · · · · · · · · · · · )· No. IPR2015-01776
`·7· · · · · · · · · · · · · · · · · ·)· · · IPR2015-01780
`· · · · · · · · · · · · · · · · · · ·)· · · IPR2015-01785
`·8· ANACOR PHARMACEUTICALS, INC.,· · )
`· · · · · · · · · · · · · · · · · · ·)
`·9· · · · · · · · ·Patent Owner.· · ·)
`· · _________________________________)
`10
`
`11
`
`12· · · · · · · · · · · · · ·VOLUME I
`
`13· · · · · · ·DEPOSITION OF STEPHEN B. KAHL, Ph.D.
`
`14· · · · · · · · · ·San Francisco, California
`
`15· · · · · · · · · · Thursday, April 7, 2016
`
`16· · ·IN RE PATENT NOS. 7,582,621; 7,767,657; and 7,767,657
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24· Reported by:· LANA L. LOPER, RMR, CRR, CCP,
`· · · · · · · · · CME, CLR, CSR No. 9667
`25
`
`
`U.S. LEGAL SUPPORTU.S. LEGAL SUPPORT
`
`(415) 362-4346(415) 362-4346
`
`Page 1
`
`Anacor Exhibit 2010
`Flatwing Pharmaceuticals, Inc. v. Anacor Pharmaceuticals, Inc
`IPR2018-00171
`
`
`
`
`Stephen B. Kahl, Ph.D.Stephen B. Kahl, Ph.D.
`
`April 07, 2016April 07, 2016
`
`2
`
`·1· · · ·IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
`
`·2· · · · · ·BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`·3· _________________________________
`· · · · · · · · · · · · · · · · · · ·)
`·4· COALITION FOR AFFORDABLE DRUGS· ·)
`· · X LLC,,· · · · · · · · · · · · · )
`·5· · · · · · · · ·Petitioner,· · · ·)
`· · · · · · · · · · · · · · · · · · ·)
`·6· vs.· · · · · · · · · · · · · · · )· No. IPR2015-01776
`· · · · · · · · · · · · · · · · · · ·)· · · IPR2015-01780
`·7· · · · · · · · · · · · · · · · · ·)· · · IPR2015-01785
`· · ANACOR PHARMACEUTICALS, INC.,· · )
`·8· · · · · · · · · · · · · · · · · ·)
`· · · · · · · · · ·Patent Owner.· · ·)
`·9· _________________________________)
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18· · · · · · Deposition of STEPHEN B. KAHL, Ph.D., taken on
`
`19· behalf of Patent Owner, at One Front Street, 35th Floor,
`
`20· San Francisco, California beginning at 8:49 a.m. and
`
`21· ending at 4:48 p.m., on Thursday, April 7, 2016, before
`
`22· Lana L. Loper, RMR, CRR, CCP, CME, CLR, CSR No. 9667.
`
`23
`
`24
`
`25
`
`
`U.S. LEGAL SUPPORTU.S. LEGAL SUPPORT
`
`(415) 362-4346(415) 362-4346
`
`CFAD v. Anacor, IPR2015-01776
`ANACOR EX. 2033 - 2/583
`
`Page 2
`
`Anacor Exhibit 2010
`Flatwing Pharmaceuticals, Inc. v. Anacor Pharmaceuticals, Inc
`IPR2018-00171
`
`
`
`
`Stephen B. Kahl, Ph.D.Stephen B. Kahl, Ph.D.
`
`April 07, 2016April 07, 2016
`
`3
`
`·1· APPEARANCE OF COUNSEL:
`
`·2· FOR THE PETITIONER:
`
`·3· · · ·MERCHANT & GOULD
`
`·4· · · ·BY:· PETER A. GERGELY, ESQ.
`
`·5· · · · · · RYAN JAMES FLETCHER, ESQ.
`
`·6· · · · · · KATHLEEN OTT, ESQ.
`
`·7· · · ·1801 California Street
`
`·8· · · ·Suite 3300
`
`·9· · · ·Denver, Colorado 80202-2654
`
`10· · · ·303-357-1670
`
`11· · · ·pgergely@merchantgould.com
`
`12· · · ·rfletcher@merchantgould.com
`
`13· · · ·kott@merchantgould.com
`
`14· FOR THE PATENT OWNER:
`
`15· · · ·COVINGTON BURLING LLP
`
`16· · · ·BY:· PAUL J. BERMAN, ESQ.
`
`17· · · · · · EVAN KRYGOWSKI, ESQ.
`
`18· · · · · · CHRISTOPHER EPPICH, ESQ. (Los Angeles)
`
`19· · · ·One CityCenter
`
`20· · · ·850 Tenth Street, NW
`
`21· · · ·Washington, DC 20001-4956
`
`22· · · ·202-662-6000
`
`23· · · ·pberman@cov.com
`
`24· · · ·ekrygowski@cov.com
`
`25· · · ·ceppich@cov.com
`
`
`U.S. LEGAL SUPPORTU.S. LEGAL SUPPORT
`
`(415) 362-4346(415) 362-4346
`
`CFAD v. Anacor, IPR2015-01776
`ANACOR EX. 2033 - 3/583
`
`Page 3
`
`Anacor Exhibit 2010
`Flatwing Pharmaceuticals, Inc. v. Anacor Pharmaceuticals, Inc
`IPR2018-00171
`
`
`
`
`Stephen B. Kahl, Ph.D.Stephen B. Kahl, Ph.D.
`
`April 07, 2016April 07, 2016
`
`4
`
`·1· · · · · · · · · · · · I N D E X
`
`·2
`
`·3· WITNESS· · · · · · · · · · · · · · · · EXAMINATION
`
`·4· STEPHEN B. KAHL, Ph.D.
`
`·5· · · · · · · · ·BY MR. BERMAN· · · · · · · · 13
`
`·6
`
`·7
`
`·8
`
`·9
`
`10
`
`11
`
`12
`
`13
`
`14· QUESTIONS WITNESS INSTRUCTED NOT TO ANSWER:
`
`15· · · · · · NONE
`
`16
`
`17· INFORMATION TO BE SUPPLIED:
`
`18· · · · · · NONE
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`
`U.S. LEGAL SUPPORTU.S. LEGAL SUPPORT
`
`(415) 362-4346(415) 362-4346
`
`CFAD v. Anacor, IPR2015-01776
`ANACOR EX. 2033 - 4/583
`
`Page 4
`
`Anacor Exhibit 2010
`Flatwing Pharmaceuticals, Inc. v. Anacor Pharmaceuticals, Inc
`IPR2018-00171
`
`
`
`
`Stephen B. Kahl, Ph.D.Stephen B. Kahl, Ph.D.
`
`April 07, 2016April 07, 2016
`
`5
`
`·1· · · · · · · · · · · · E X H I B I T S
`
`·2· · · ·COALITION FOR AFFORDABLE DRUGS X LLC, vs. ANACOR
`
`·3· · · · · · · · · · ·PHARMACEUTICALS, INC.
`
`·4· · · · · · · · · · STEPHEN B. KAHL, Ph.D.
`
`·5· · · · · · · · · · · · ·April 7, 2016
`
`·6· EXHIBIT· · · · · · · · · · · · · · · · · ·PAGE
`
`·7· Exhibit 1· · · Patent Owner Anacor· · · · · 15
`
`·8· · · · · · · · ·Pharmaceuticals, Inc.'s
`
`·9· · · · · · · · ·Notice of Deposition of
`
`10· · · · · · · · ·Stephen B. Kahl, Ph.D. in
`
`11· · · · · · · · ·re Case No. IPR2015-01776
`
`12· Exhibit 2· · · Patent Owner Anacor· · · · · 16
`
`13· · · · · · · · ·Pharmaceuticals, Inc.'s
`
`14· · · · · · · · ·Notice of Deposition of
`
`15· · · · · · · · ·Stephen B. Kahl, Ph.D. in
`
`16· · · · · · · · ·re Case No. IPR2015-01780
`
`17· Exhibit 3· · · Patent Owner Anacor· · · · · 16
`
`18· · · · · · · · ·Pharmaceuticals, Inc.'s
`
`19· · · · · · · · ·Notice of Deposition of
`
`20· · · · · · · · ·Stephen B. Kahl, Ph.D. in
`
`21· · · · · · · · ·re Case No. IPR2015-01785
`
`22
`
`23
`
`24
`
`25
`
`
`U.S. LEGAL SUPPORTU.S. LEGAL SUPPORT
`
`(415) 362-4346(415) 362-4346
`
`CFAD v. Anacor, IPR2015-01776
`ANACOR EX. 2033 - 5/583
`
`Page 5
`
`Anacor Exhibit 2010
`Flatwing Pharmaceuticals, Inc. v. Anacor Pharmaceuticals, Inc
`IPR2018-00171
`
`
`
`
`Stephen B. Kahl, Ph.D.Stephen B. Kahl, Ph.D.
`
`April 07, 2016April 07, 2016
`
`6
`
`·1· · · · · · · · · · · · E X H I B I T S
`
`·2· · · ·COALITION FOR AFFORDABLE DRUGS X LLC, vs. ANACOR
`
`·3· · · · · · · · · · ·PHARMACEUTICALS, INC.
`
`·4· · · · · · · · · · STEPHEN B. KAHL, Ph.D.
`
`·5· · · · · · · · · · · · ·April 7, 2016
`
`·6· EXHIBIT· · · · · · · · · · · · · · · · · ·PAGE
`
`·7· Exhibit 1006· ·Declaration of Stephen· · · ·25
`
`·8· · · · · · · · ·Kahl, Ph.D. in Support of
`
`·9· · · · · · · · ·Petition for Inter Partes
`
`10· · · · · · · · ·Review of Patent No.
`
`11· · · · · · · · ·7,582,621
`
`12· Exhibit 1009-1 Declaration of Stephen· · · ·32
`
`13· · · · · · · · ·Kahl, Ph.D. in Supportof
`
`14· · · · · · · · ·First Petition for Inter
`
`15· · · · · · · · ·Partes Review of Patent
`
`16· · · · · · · · ·No. 7,767,657
`
`17· Exhibit 1009-2 Declaration of Stephen· · · ·33
`
`18· · · · · · · · ·Kahl, Ph.D., in Support of
`
`19· · · · · · · · ·Second Petition for Inter
`
`20· · · · · · · · ·Partes Review of Patent
`
`21· · · · · · · · ·No. 7,767,657
`
`22· Exhibit 1007· ·University of California· · ·56
`
`23· · · · · · · · ·San Francisco Curriculum
`
`24· · · · · · · · ·Vitae Stephen B. Kahl
`
`25
`
`
`U.S. LEGAL SUPPORTU.S. LEGAL SUPPORT
`
`(415) 362-4346(415) 362-4346
`
`CFAD v. Anacor, IPR2015-01776
`ANACOR EX. 2033 - 6/583
`
`Page 6
`
`Anacor Exhibit 2010
`Flatwing Pharmaceuticals, Inc. v. Anacor Pharmaceuticals, Inc
`IPR2018-00171
`
`
`
`Stephen B. Kahl, Ph.D.
`Stephen B. Kahl, Ph.D.
`April 07, 2016
`April 07, 2016
`
`7
`
`·1· · · · · · · · · · · · E X H I B I T S
`
`·2· · · ·COALITION FOR AFFORDABLE DRUGS X LLC, vs. ANACOR
`
`·3· · · · · · · · · · ·PHARMACEUTICALS, INC.
`
`·4· · · · · · · · · · STEPHEN B. KAHL, Ph.D.
`
`·5· · · · · · · · · · · · ·April 7, 2016
`
`·6· EXHIBIT· · · · · · · · · · · · · · · · · ·PAGE
`
`·7· Exhibit 4· · · Handwritten notes re· · · · ·60
`
`·8· · · · · · · · ·Austin
`
`·9· Exhibit 5· · · Handwritten notes re· · · · ·61
`
`10· · · · · · · · ·Brehove
`
`11· Exhibit 6· · · Handwritten notes re· · · · ·62
`
`12· · · · · · · · ·Freeman
`
`13· Exhibit 7· · · Handwritten notes re· · · · ·63
`
`14· · · · · · · · ·Patent Owner Exhibits
`
`15· Exhibit 8· · · Handwritten notes re· · · · ·64
`
`16· · · · · · · · ·Kerydin
`
`17· Exhibit 9· · · Handwritten notes re· · · · ·64
`
`18· · · · · · · · ·Groziak
`
`19· Exhibit 10· · ·United States Patent· · · · ·66
`
`20· · · · · · · · ·Application Publication,
`
`21· · · · · · · · ·US 2002/0165121 A1
`
`22
`
`23
`
`24
`
`25
`
`U.S. LEGAL SUPPORT
`U.S. LEGAL SUPPORT
`(415) 362-4346
`(415) 362-4346
`
`Page 7
`
`Anacor Exhibit 2010
`Flatwing Pharmaceuticals, Inc. v. Anacor Pharmaceuticals, Inc
`IPR2018-00171
`
`
`
`
`Stephen B. Kahl, Ph.D.Stephen B. Kahl, Ph.D.
`
`April 07, 2016April 07, 2016
`
`8
`
`·1· · · · · · · · · · · · E X H I B I T S
`
`·2· · · ·COALITION FOR AFFORDABLE DRUGS X LLC, vs. ANACOR
`
`·3· · · · · · · · · · ·PHARMACEUTICALS, INC.
`
`·4· · · · · · · · · · STEPHEN B. KAHL, Ph.D.
`
`·5· · · · · · · · · · · · ·April 7, 2016
`
`·6· EXHIBIT· · · · · · · · · · · · · · · · · ·PAGE
`
`·7· Exhibit 11· · ·Declaration of Stephen· · · ·70
`
`·8· · · · · · · · ·Kahl, Ph.D. in Support of
`
`·9· · · · · · · · ·Petition for Inter Partes
`
`10· · · · · · · · ·Review of Patent No.
`
`11· · · · · · · · ·7,582,621
`
`12· Exhibit 12· · ·International Application· · 71
`
`13· · · · · · · · ·Published Under the Patent
`
`14· · · · · · · · ·Cooperation Treaty (PCT)
`
`15· · · · · · · · ·WO 95/33754 (Austin)
`
`16· Exhibit 13· · ·International Application· · 72
`
`17· · · · · · · · ·Published Under the Patent
`
`18· · · · · · · · ·Cooperation Treaty (PCT)
`
`19· · · · · · · · ·WO 03/009689 A1 (Freeman)
`
`20· Exhibit 14· · ·American Journal of· · · · · 74
`
`21· · · · · · · · ·Therapeutics 8, 321-328
`
`22· · · · · · · · ·(2001) Boron Therapeutics
`
`23· · · · · · · · ·on the Horizon by Michael
`
`24· · · · · · · · ·P. Groziak
`
`25
`
`
`U.S. LEGAL SUPPORTU.S. LEGAL SUPPORT
`
`(415) 362-4346(415) 362-4346
`
`CFAD v. Anacor, IPR2015-01776
`ANACOR EX. 2033 - 8/583
`
`Page 8
`
`Anacor Exhibit 2010
`Flatwing Pharmaceuticals, Inc. v. Anacor Pharmaceuticals, Inc
`IPR2018-00171
`
`
`
`
`Stephen B. Kahl, Ph.D.Stephen B. Kahl, Ph.D.
`
`April 07, 2016April 07, 2016
`
`9
`
`·1· · · · · · · · · · · · E X H I B I T S
`
`·2· · · ·COALITION FOR AFFORDABLE DRUGS X LLC, vs. ANACOR
`
`·3· · · · · · · · · · ·PHARMACEUTICALS, INC.
`
`·4· · · · · · · · · · STEPHEN B. KAHL, Ph.D.
`
`·5· · · · · · · · · · · · ·April 7, 2016
`
`·6· EXHIBIT· · · · · · · · · · · · · · · · · ·PAGE
`
`·7· Exhibit 15· · ·Chemical structural· · · · · 79
`
`·8· · · · · · · · ·diagram
`
`·9· Exhibit 16· · ·Chemical structural· · · · · 87
`
`10· · · · · · · · ·diagram
`
`11· Exhibit 17· · ·Chemical structural· · · · · 90
`
`12· · · · · · · · ·diagram
`
`13· Exhibit 18· · ·Chemical structural· · · · · 93
`
`14· · · · · · · · ·diagram
`
`15· Exhibit 19· · ·Chemical structural· · · · ·102
`
`16· · · · · · · · ·diagram
`
`17· Exhibit 20· · ·Chemical structural· · · · ·104
`
`18· · · · · · · · ·diagram
`
`19· Exhibit 21· · ·Chemical structural· · · · ·110
`
`20· · · · · · · · ·diagram
`
`21· Exhibit 22· · ·Chemical structural· · · · ·121
`
`22· · · · · · · · ·diagram
`
`23· Exhibit 23· · ·Chemical structural· · · · ·127
`
`24· · · · · · · · ·diagram
`
`25
`
`
`U.S. LEGAL SUPPORTU.S. LEGAL SUPPORT
`
`(415) 362-4346(415) 362-4346
`
`Page 9
`
`Anacor Exhibit 2010
`Flatwing Pharmaceuticals, Inc. v. Anacor Pharmaceuticals, Inc
`IPR2018-00171
`
`
`
`
`Stephen B. Kahl, Ph.D.Stephen B. Kahl, Ph.D.
`
`April 07, 2016April 07, 2016
`
`10
`
`·1· · · · · · · · · · · · E X H I B I T S
`
`·2· · · ·COALITION FOR AFFORDABLE DRUGS X LLC, vs. ANACOR
`
`·3· · · · · · · · · · ·PHARMACEUTICALS, INC.
`
`·4· · · · · · · · · · STEPHEN B. KAHL, Ph.D.
`
`·5· · · · · · · · · · · · ·April 7, 2016
`
`·6· EXHIBIT· · · · · · · · · · · · · · · · · ·PAGE
`
`·7· Exhibit 24· · ·Chemical structural· · · · ·137
`
`·8· · · · · · · · ·diagram
`
`·9· Exhibit 25· · ·Chemical structural· · · · ·139
`
`10· · · · · · · · ·diagram
`
`11· Exhibit 26· · ·Chemical structural· · · · ·142
`
`12· · · · · · · · ·diagram
`
`13· Exhibit 27· · ·Chemical structural· · · · ·144
`
`14· · · · · · · · ·diagram
`
`15· Exhibit 28· · ·Chemical structural· · · · ·147
`
`16· · · · · · · · ·diagram
`
`17· Exhibit 29· · ·Chemical structural· · · · ·149
`
`18· · · · · · · · ·diagram
`
`19· Exhibit 30· · ·Chemical structural· · · · ·162
`
`20· · · · · · · · ·diagram
`
`21· Exhibit 31· · ·Chemical structural· · · · ·166
`
`22· · · · · · · · ·diagram
`
`23· Exhibit 32· · ·Chemical structural· · · · ·171
`
`24· · · · · · · · ·diagram
`
`25
`
`
`U.S. LEGAL SUPPORTU.S. LEGAL SUPPORT
`
`(415) 362-4346(415) 362-4346
`
`CFAD v. Anacor, IPR2015-01776
`ANACOR EX. 2033 - 10/583
`
`Page 10
`
`Anacor Exhibit 2010
`Flatwing Pharmaceuticals, Inc. v. Anacor Pharmaceuticals, Inc
`IPR2018-00171
`
`
`
`
`Stephen B. Kahl, Ph.D.Stephen B. Kahl, Ph.D.
`
`April 07, 2016April 07, 2016
`
`11
`
`·1· · · · · · · · · · · · E X H I B I T S
`
`·2· · · ·COALITION FOR AFFORDABLE DRUGS X LLC, vs. ANACOR
`
`·3· · · · · · · · · · ·PHARMACEUTICALS, INC.
`
`·4· · · · · · · · · · STEPHEN B. KAHL, Ph.D.
`
`·5· · · · · · · · · · · · ·April 7, 2016
`
`·6· EXHIBIT· · · · · · · · · · · · · · · · · ·PAGE
`
`·7· Exhibit 33· · ·Chemical structural· · · · ·173
`
`·8· · · · · · · · ·diagram
`
`·9· Exhibit 34· · ·Chemical structural· · · · ·177
`
`10· · · · · · · · ·diagram
`
`11· Exhibit 35· · ·Chemical structural· · · · ·179
`
`12· · · · · · · · ·diagram
`
`13· Exhibit 36· · ·Chemical structural· · · · ·185
`
`14· · · · · · · · ·diagram
`
`15· Exhibit 37· · ·Chemical structural· · · · ·192
`
`16· · · · · · · · ·diagram
`
`17· Exhibit 38· · ·Chemical structural· · · · ·201
`
`18· · · · · · · · ·diagram
`
`19· Exhibit 39· · ·Chemical structural· · · · ·204
`
`20· · · · · · · · ·diagram
`
`21· Exhibit 40· · ·Chemical structural· · · · ·208
`
`22· · · · · · · · ·diagram
`
`23· Exhibit 41· · ·Chemical structural· · · · ·213
`
`24· · · · · · · · ·diagram
`
`25
`
`
`U.S. LEGAL SUPPORTU.S. LEGAL SUPPORT
`
`(415) 362-4346(415) 362-4346
`
`CFAD v. Anacor, IPR2015-01776
`ANACOR EX. 2033 - 11/583
`
`Page 11
`
`Anacor Exhibit 2010
`Flatwing Pharmaceuticals, Inc. v. Anacor Pharmaceuticals, Inc
`IPR2018-00171
`
`
`
`
`Stephen B. Kahl, Ph.D.Stephen B. Kahl, Ph.D.
`
`April 07, 2016April 07, 2016
`
`12
`
`·1· · · · · · · · · · · · E X H I B I T S
`
`·2· · · ·COALITION FOR AFFORDABLE DRUGS X LLC, vs. ANACOR
`
`·3· · · · · · · · · · ·PHARMACEUTICALS, INC.
`
`·4· · · · · · · · · · STEPHEN B. KAHL, Ph.D.
`
`·5· · · · · · · · · · · · ·April 7, 2016
`
`·6· EXHIBIT· · · · · · · · · · · · · · · · · ·PAGE
`
`·7· Exhibit 42· · ·Chemical structural· · · · ·214
`
`·8· · · · · · · · ·diagram
`
`·9· Exhibit 43· · ·Chemical structural· · · · ·218
`
`10· · · · · · · · ·diagram
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`
`U.S. LEGAL SUPPORTU.S. LEGAL SUPPORT
`
`(415) 362-4346(415) 362-4346
`
`Page 12
`
`Anacor Exhibit 2010
`Flatwing Pharmaceuticals, Inc. v. Anacor Pharmaceuticals, Inc
`IPR2018-00171
`
`
`
`
`Stephen B. Kahl, Ph.D.Stephen B. Kahl, Ph.D.
`
`April 07, 2016April 07, 2016
`
`13
`
`·1· · · San Francisco, California; Thursday, April 7, 2016
`
`·2· · · · · · · · · · ·8:49 a.m. - 4:48 p.m.
`
`·3· · · · · · · · · · · · · · ·- - -
`
`·4· · · · · · · · · · STEPHEN B. KAHL, Ph.D.,
`
`·5· · · · · ·having been first administered an oath
`
`·6· · · · · ·in accordance with CCP Section 2094, was
`
`·7· · · · · ·examined and testified as follows:
`
`·8· · · · · · · · · · · · · EXAMINATION
`
`·9· BY MR. BERMAN:
`
`10· · · ·Q· ·Prof. Kahl, thank you very much for being here
`
`11· today.
`
`12· · · ·A· ·Thank you.
`
`13· · · ·Q· ·My name is Paul Berman.· I'm counsel for Anacor
`
`14· Pharmaceuticals.
`
`15· · · · · ·Can you please state your name for the record?
`
`16· · · ·A· ·My name is Stephen Bruce Kahl.
`
`17· · · ·Q· ·And could you please state your address and
`
`18· occupation also, for the record?
`
`19· · · ·A· ·My home address is One Lerida Court, in Portola
`
`20· Valley, California 94028.
`
`21· · · · · ·And I'm a professor of pharmaceutical chemistry
`
`22· at the University of California in San Francisco.
`
`23· · · ·Q· ·Prof. Kahl, is there any reason why you cannot
`
`24· testify truthfully today?
`
`25· · · ·A· ·No.
`
`
`U.S. LEGAL SUPPORTU.S. LEGAL SUPPORT
`
`(415) 362-4346(415) 362-4346
`
`CFAD v. Anacor, IPR2015-01776
`ANACOR EX. 2033 - 13/583
`
`YVer1f
`
`Page 13
`
`Anacor Exhibit 2010
`Flatwing Pharmaceuticals, Inc. v. Anacor Pharmaceuticals, Inc
`IPR2018-00171
`
`
`
`
`Stephen B. Kahl, Ph.D.Stephen B. Kahl, Ph.D.
`
`April 07, 2016April 07, 2016
`
`14
`
`·1· · · ·Q· ·You're not on any medication that makes it hard
`
`·2· to remember things or anything like that?
`
`·3· · · ·A· ·No.
`
`·4· · · ·Q· ·Okay.· Prof. Kahl, have you ever had your
`
`·5· deposition taken before?
`
`·6· · · ·A· ·Yes.
`
`·7· · · ·Q· ·When was that?
`
`·8· · · ·A· ·In 1989.
`
`·9· · · ·Q· ·Okay.· Let me review briefly the ground rules
`
`10· for depositions.
`
`11· · · · · ·I get to ask questions and you get to answer
`
`12· them.
`
`13· · · · · ·If your counsel objects to the question, some
`
`14· legal or other problem, unless it's an objection
`
`15· pertaining to privilege, attorney-client privilege, you
`
`16· need to answer the question.
`
`17· · · · · ·If it's a privileged question, let me know or
`
`18· your counsel will let me know, and we can talk about
`
`19· consulting to resolve the privilege question before you
`
`20· give the answer.· But that's the exception to the rule,
`
`21· which is that when I ask a question, you answer it.
`
`22· Okay?
`
`23· · · · · ·If you need to take a break, let me know.· We'll
`
`24· try and take a break at the next available moment we can.
`
`25· · · ·A· ·Sure.
`
`
`U.S. LEGAL SUPPORTU.S. LEGAL SUPPORT
`
`(415) 362-4346(415) 362-4346
`
`CFAD v. Anacor, IPR2015-01776
`ANACOR EX. 2033 - 14/583
`
`YVer1f
`
`Page 14
`
`Anacor Exhibit 2010
`Flatwing Pharmaceuticals, Inc. v. Anacor Pharmaceuticals, Inc
`IPR2018-00171
`
`
`
`
`Stephen B. Kahl, Ph.D.Stephen B. Kahl, Ph.D.
`
`April 07, 2016April 07, 2016
`
`15
`
`·1· · · ·Q· ·And have you ever testified at trial before?
`
`·2· · · ·A· ·No.
`
`·3· · · ·Q· ·Since that deposition in 1987, have you had your
`
`·4· deposition taken since then, or was it 1989?
`
`·5· · · ·A· ·1989.
`
`·6· · · ·Q· ·I beg your pardon.
`
`·7· · · ·A· ·I have not since then.
`
`·8· · · ·Q· ·I'm asking the reporter to mark for
`
`·9· identification as Kahl Deposition 1 a copy of a patent
`
`10· owner -- Anacor Pharmaceuticals, Inc., notice of
`
`11· deposition of Stephen B. Kahl, Ph.D.
`
`12· · · · · ·MR. GERGELY:· After he identifies the exhibit,
`
`13· she'll mark it and hand it to you.· This is the official
`
`14· copy for you to look at.
`
`15· · · ·A· ·Okay.
`
`16· · · · · ·(Patent Owners' Exhibit 1 was marked for
`
`17· · · · · ·identification.)
`
`18· BY MR. BERMAN:
`
`19· · · ·Q· ·Dr. Kahl, have you ever seen this document
`
`20· before?
`
`21· · · ·A· ·This document?
`
`22· · · ·Q· ·Yes.
`
`23· · · ·A· ·No, not to my knowledge.
`
`24· · · ·Q· ·All right.· I'm asking the reporter to mark as
`
`25· Kahl Deposition Exhibit No. 2 a copy of patent owner
`
`
`U.S. LEGAL SUPPORTU.S. LEGAL SUPPORT
`
`(415) 362-4346(415) 362-4346
`
`CFAD v. Anacor, IPR2015-01776
`ANACOR EX. 2033 - 15/583
`
`YVer1f
`
`Page 15
`
`Anacor Exhibit 2010
`Flatwing Pharmaceuticals, Inc. v. Anacor Pharmaceuticals, Inc
`IPR2018-00171
`
`
`
`
`Stephen B. Kahl, Ph.D.Stephen B. Kahl, Ph.D.
`
`April 07, 2016April 07, 2016
`
`16
`
`·1· Anacor Pharmaceuticals, Inc., notice of deposition of
`
`·2· Stephen B. Kahl in patent -- in IPR 2015-01780.
`
`·3· · · · · ·(Patent Owners' Exhibit 2 was marked for
`
`·4· · · · · ·identification.)
`
`·5· BY MR. BERMAN:
`
`·6· · · ·Q· ·Have you ever seen this document before --
`
`·7· · · ·A· ·No, I do not believe that I have.
`
`·8· · · ·Q· ·And I'm asking the reporter to mark as Kahl
`
`·9· Exhibit -- Deposition Exhibit No. 3 a copy of patent --
`
`10· Anacor Pharmaceuticals' Notice of Deposition of Stephen
`
`11· B. Kahl, Ph.D, in IPR2015-01785.
`
`12· · · · · ·(Patent Owners' Exhibit 3 was marked for
`
`13· · · · · ·identification.)
`
`14· BY MR. BERMAN:
`
`15· · · ·Q· ·Dr. Kahl, have you ever seen that document
`
`16· before?
`
`17· · · ·A· ·No, I don't believe I have.
`
`18· · · ·Q· ·Dr. Kahl, how did you come to know that you
`
`19· needed to be here for deposition today?
`
`20· · · ·A· ·I was informed by counsel that I had needed to
`
`21· be here today.
`
`22· · · ·Q· ·Which counsel, in particular?
`
`23· · · ·A· ·These gentlemen sitting to my right, and lady.
`
`24· · · ·Q· ·Which -- do you remember who of the three in
`
`25· particular made that call or sent you an e-mail?
`
`
`U.S. LEGAL SUPPORTU.S. LEGAL SUPPORT
`
`(415) 362-4346(415) 362-4346
`
`Page 16
`
`Anacor Exhibit 2010
`Flatwing Pharmaceuticals, Inc. v. Anacor Pharmaceuticals, Inc
`IPR2018-00171
`
`
`
`
`Stephen B. Kahl, Ph.D.Stephen B. Kahl, Ph.D.
`
`April 07, 2016April 07, 2016
`
`17
`
`·1· · · ·A· ·I believe it was Ryan Fletcher.
`
`·2· · · ·Q· ·Okay.· Are you represented by counsel here
`
`·3· today?
`
`·4· · · ·A· ·No.
`
`·5· · · ·Q· ·No.
`
`·6· · · · · ·So you don't have an engagement letter with
`
`·7· Merchant & Gould or any of these individuals?
`
`·8· · · · · ·MR. GERGELY:· I mean, he's our expert.· And
`
`·9· we're representing him in connection with the deposition,
`
`10· but like --
`
`11· BY MR. BERMAN:
`
`12· · · ·Q· ·Do you have an engagement letter?
`
`13· · · · · ·MR. GERGELY:· -- like a formal attorney-client
`
`14· thing?
`
`15· · · · · ·MR. BERMAN:· If you have an objection, state,
`
`16· objection.
`
`17· · · · · ·If he's got a problem understanding the
`
`18· question, he can tell me.
`
`19· BY MR. BERMAN:
`
`20· · · ·Q· ·Do you have an engagement letter with Merchant &
`
`21· Gould?
`
`22· · · ·A· ·Yes.
`
`23· · · ·Q· ·Are they acting as your counsel today?
`
`24· · · ·A· ·I believe that's the case, yes.
`
`25· · · ·Q· ·Does your engagement letter specify that you are
`
`
`U.S. LEGAL SUPPORTU.S. LEGAL SUPPORT
`
`(415) 362-4346(415) 362-4346
`
`CFAD v. Anacor, IPR2015-01776
`ANACOR EX. 2033 - 17/583
`
`YVer1f
`
`Page 17
`
`Anacor Exhibit 2010
`Flatwing Pharmaceuticals, Inc. v. Anacor Pharmaceuticals, Inc
`IPR2018-00171
`
`
`
`
`Stephen B. Kahl, Ph.D.Stephen B. Kahl, Ph.D.
`
`April 07, 2016April 07, 2016
`
`18
`
`·1· retaining them as counsel?
`
`·2· · · ·A· ·I honestly have not looked at the engagement
`
`·3· letter.· I cannot say.· They have re --
`
`·4· · · ·Q· ·Do you want to complete that sentence?
`
`·5· · · ·A· ·They have retained me to advise them on these
`
`·6· matters.
`
`·7· · · ·Q· ·Okay.· They have retained you, not you retained
`
`·8· them, correct?
`
`·9· · · ·A· ·Correct.
`
`10· · · ·Q· ·Have you ever testified at trial?
`
`11· · · ·A· ·No.
`
`12· · · ·Q· ·And how did you prepare for this deposition?
`
`13· · · ·A· ·I reread my declaration.
`
`14· · · · · ·I read the various patents and documents
`
`15· involved in the case.
`
`16· · · ·Q· ·You have three declarations in these three
`
`17· proceedings, correct?
`
`18· · · ·A· ·Correct.
`
`19· · · ·Q· ·Did you read one, two, or three of them in
`
`20· preparation for this deposition?
`
`21· · · ·A· ·I read one.
`
`22· · · ·Q· ·Which one?
`
`23· · · ·A· ·Inter partes review of Patent No. 7,582,621.
`
`24· · · ·Q· ·So you didn't read the other two declarations,
`
`25· one with respect to the '657 patent?
`
`
`U.S. LEGAL SUPPORTU.S. LEGAL SUPPORT
`
`(415) 362-4346(415) 362-4346
`
`CFAD v. Anacor, IPR2015-01776
`ANACOR EX. 2033 - 18/583
`
`YVer1f
`
`Page 18
`
`Anacor Exhibit 2010
`Flatwing Pharmaceuticals, Inc. v. Anacor Pharmaceuticals, Inc
`IPR2018-00171
`
`
`
`
`Stephen B. Kahl, Ph.D.Stephen B. Kahl, Ph.D.
`
`April 07, 2016April 07, 2016
`
`19
`
`·1· · · ·A· ·I did not reread them, no.
`
`·2· · · ·Q· ·Dr. Kahl, I notice before you a folder of
`
`·3· documents on yellow.· They appear to be handwriting on
`
`·4· it.· I can't read them --
`
`·5· · · ·A· ·Yes.
`
`·6· · · ·Q· ·-- and others.
`
`·7· · · · · ·You intend to refer to those during this
`
`·8· deposition?
`
`·9· · · ·A· ·I do.
`
`10· · · ·Q· ·I would like to have each one separately marked
`
`11· as an exhibit.
`
`12· · · · · ·We'll copy them during the break.· And we're
`
`13· certainly happy to give them back to you.
`
`14· · · ·A· ·Certainly.
`
`15· · · ·Q· ·I don't know what you have, so if you want to
`
`16· pass them to me, I'll give them to the reporter and we
`
`17· can worry about the content of them later.
`
`18· · · · · ·MR. GERGELY:· Paul, do you mind if I just take a
`
`19· quick glance before he does that?
`
`20· · · · · ·MR. BERMAN:· You can glance at them, but they're
`
`21· all going -- they're going to be exhibits.
`
`22· · · · · ·You can glance at them now or later.
`
`23· · · · · ·THE WITNESS:· What we talked about yesterday.
`
`24· · · · · ·MR. GERGELY:· Just give me a minute.
`
`25· · · · · ·Okay.· Do you want them now?
`
`
`U.S. LEGAL SUPPORTU.S. LEGAL SUPPORT
`
`(415) 362-4346(415) 362-4346
`
`CFAD v. Anacor, IPR2015-01776
`ANACOR EX. 2033 - 19/583
`
`YVer1f
`
`Page 19
`
`Anacor Exhibit 2010
`Flatwing Pharmaceuticals, Inc. v. Anacor Pharmaceuticals, Inc
`IPR2018-00171
`
`
`
`
`Stephen B. Kahl, Ph.D.Stephen B. Kahl, Ph.D.
`
`April 07, 2016April 07, 2016
`
`20
`
`·1· · · · · ·MR. BERMAN:· Well, I would like to have them
`
`·2· marked as exhibits now.
`
`·3· · · · · ·We can have them -- we can wait until we make
`
`·4· copies.
`
`·5· · · · · ·MR. GERGELY:· It's up to you, whatever you want.
`
`·6· · · · · ·If you want to take a five-minute break and make
`
`·7· copies --
`
`·8· · · · · ·MR. BERMAN:· Why don't we -- that would be fine.
`
`·9· · · · · ·Thank you.
`
`10· · · · · ·(Discussion off the record.)
`
`11· BY MR. BERMAN:
`
`12· · · ·Q· ·We can go back on.
`
`13· · · · · ·Dr. Kahl, I was -- before we went off the
`
`14· record, I was asking you about documents you reviewed in
`
`15· preparation for this deposition.
`
`16· · · ·A· ·Uh-huh.
`
`17· · · ·Q· ·I would like to be a little more specific.
`
`18· · · · · ·Did you review U.S. Patent No. 7,767,657?
`
`19· · · ·A· ·Can you give me the author of that?
`
`20· · · ·Q· ·It's the patent in the second two -- can you
`
`21· hand me a copy of it?
`
`22· · · · · ·Can we refer to it as the '657 patent?
`
`23· · · · · ·The inventors are Stephen J. Baker, Tsutomu
`
`24· Akama --
`
`25· · · ·A· ·Uh-huh, yes.
`
`
`U.S. LEGAL SUPPORTU.S. LEGAL SUPPORT
`
`(415) 362-4346(415) 362-4346
`
`Page 20
`
`Anacor Exhibit 2010
`Flatwing Pharmaceuticals, Inc. v. Anacor Pharmaceuticals, Inc
`IPR2018-00171
`
`
`
`
`Stephen B. Kahl, Ph.D.Stephen B. Kahl, Ph.D.
`
`April 07, 2016April 07, 2016
`
`21
`
`·1· · · ·Q· ·-- and eight or nine other people.
`
`·2· · · · · ·Did you review that patent?
`
`·3· · · ·A· ·I did.
`
`·4· · · ·Q· ·Did you review U.S. Patent No. 7,582,621 by the
`
`·5· same inventors?
`
`·6· · · ·A· ·Yes.
`
`·7· · · ·Q· ·May we refer in this deposition to the 7,767,657
`
`·8· as the '657 patent?
`
`·9· · · ·A· ·Yes.
`
`10· · · ·Q· ·And may we refer to 7,582,621 as the '621
`
`11· patent?
`
`12· · · ·A· ·Yes.
`
`13· · · ·Q· ·Specifically, what other documents did you
`
`14· review in preparation for this deposition?
`
`15· · · ·A· ·You're copying several of them at the moment, so
`
`16· I would have to be able to see the -- I can give you the
`
`17· authors.
`
`18· · · ·Q· ·Okay.
`
`19· · · ·A· ·Groziak.
`
`20· · · ·Q· ·Please.
`
`21· · · · · ·Uh-huh.
`
`22· · · ·A· ·The review by Groziak.
`
`23· · · · · ·The patent of Austin, et al.
`
`24· · · ·Q· ·Uh-huh.
`
`25· · · ·A· ·The patent of Brehove, et al.; the patent of
`
`
`U.S. LEGAL SUPPORTU.S. LEGAL SUPPORT
`
`(415) 362-4346(415) 362-4346
`
`CFAD v. Anacor, IPR2015-01776
`ANACOR EX. 2033 - 21/583
`
`YVer1f
`
`Page 21
`
`Anacor Exhibit 2010
`Flatwing Pharmaceuticals, Inc. v. Anacor Pharmaceuticals, Inc
`IPR2018-00171
`
`
`
`
`Stephen B. Kahl, Ph.D.Stephen B. Kahl, Ph.D.
`
`April 07, 2016April 07, 2016
`
`22
`
`·1· Freeman, et al.
`
`·2· · · · · ·Oh, I reviewed all of the documents in the
`
`·3· Anacor response, which in -- and I don't have a list in
`
`·4· front of me, so I can't specifically refer to those.
`
`·5· · · ·Q· ·Uh-huh.
`
`·6· · · · · ·Okay.· Anything else?
`
`·7· · · ·A· ·I think that's an accurate list.
`
`·8· · · ·Q· ·In the proceeding concerning the '621 patent,
`
`·9· did you review any documents that were not identified in
`
`10· your declaration or not identified in Anacor's response?
`
`11· · · ·A· ·Not to my knowledge.
`
`12· · · ·Q· ·In the proceeding concerning the '657 patent --
`
`13· in the proceedings concerning the '657 patent, did you
`
`14· review in preparation for this deposition any documents
`
`15· that were not cited in your declaration or in Anacor's
`
`16· responses?
`
`17· · · ·A· ·Not to my knowledge.
`
`18· · · ·Q· ·Okay.· Did you meet with anybody in preparation
`
`19· for this deposition?
`
`20· · · ·A· ·Yes.
`
`21· · · ·Q· ·Who?
`
`22· · · ·A· ·Mr. Gergely, Mr. Fletcher, Ms. Ott.
`
`23· · · ·Q· ·Was there one meeting or more than one meeting?
`
`24· · · ·A· ·There was more than one meeting.
`
`25· · · ·Q· ·And when were those meetings?
`
`
`U.S. LEGAL SUPPORTU.S. LEGAL SUPPORT
`
`(415) 362-4346(415) 362-4346
`
`CFAD v. Anacor, IPR2015-01776
`ANACOR EX. 2033 - 22/583
`
`YVer1f
`
`Page 22
`
`Anacor Exhibit 2010
`Flatwing Pharmaceuticals, Inc. v. Anacor Pharmaceuticals, Inc
`IPR2018-00171
`
`
`
`
`Stephen B. Kahl, Ph.D.Stephen B. Kahl, Ph.D.
`
`April 07, 2016April 07, 2016
`
`23
`
`·1· · · ·A· ·Yesterday, the 6th of April; last Thursday,
`
`·2· which would have been -- whatever day that was.
`
`·3· · · ·Q· ·March 31?
`
`·4· · · ·A· ·Yes.
`
`·5· · · · · ·And, I believe, last Wednesday, March 30th.
`
`·6· · · ·Q· ·How long was the meeting on March 30th?
`
`·7· · · ·A· ·March 30th was Wednesday.
`
`·8· · · · · ·It would have been approximately four hours.
`
`·9· · · ·Q· ·And where was that meeting?
`
`10· · · ·A· ·That meeting was in the Pickwick Hotel in
`
`11· San Francisco.
`
`12· · · ·Q· ·And the meeting on March 31st, how long was it?
`
`13· · · ·A· ·Approximately four hours.
`
`14· · · ·Q· ·Where was it?
`
`15· · · ·A· ·In the Pickwick Hotel.
`
`16· · · ·Q· ·And the meeting yesterday, where was it?
`
`17· · · ·A· ·It was in the Harbor Court Hotel.
`
`18· · · ·Q· ·Is that in San Francisco?
`
`19· · · ·A· ·Yes.
`
`20· · · ·Q· ·And how long was that?
`
`21· · · ·A· ·About two and a half hours.
`
`22· · · ·Q· ·Was anybody other than the three of these
`
`23· lawyers present at any of those meetings?
`
`24· · · ·A· ·No.
`
`25· · · ·Q· ·Did you have any conference calls or other
`
`
`U.S. LEGAL SUPPORTU.S. LEGAL SUPPORT
`
`(415) 362-4346(415) 362-4346
`
`Page 23
`
`Anacor Exhibit 2010
`Flatwing Pharmaceuticals, Inc. v. Anacor Pharmaceuticals, Inc
`IPR2018-00171
`
`
`
`
`Stephen B. Kahl, Ph.D.Stephen B. Kahl, Ph.D.
`
`April 07, 2016April 07, 2016
`
`24
`
`·1· communications in preparation for this deposition?
`
`·2· · · ·A· ·No.
`
`·3· · · ·Q· ·Did you speak with anybody else in preparation
`
`·4· for this deposition?
`
`·5· · · ·A· ·No.
`
`·6· · · ·Q· ·Did you e-mail or otherwise communicate with
`
`·7· anyone in preparation for this deposition?
`
`·8· · · ·A· ·No.
`
`·9· · · · · ·MR. BERMAN:· I'm asking the reporter to mark as
`
`10· Kahl Deposition Exhibit 1006 a copy of the declaration of
`
`11· Stephen Kahl, Ph.D., in support of petition for
`
`12· inter partes review of patent No. 7,582,621.
`
`13· · · · · ·MR. GERGELY:· So the numbering protocol is, if
`
`14· it's a new document that's not a record, it's going to go
`
`15· 1, 2, 3, but if it's already of record, we're just going
`
`16· to use the original?
`
`17· · · · · ·MR. BERMAN:· Yes, with the exception of Exhibits
`
`18· 1009, which would be 1009-1 and 1009-2.
`
`19· · · · · ·MR. GERGELY:· Okay.
`
`20· · · · · ·MR. BERMAN:· And if they're similar --
`
`21· · · · · ·MR. GERGELY:· Okay.
`
`22· · · · · ·MR. BERMAN:· -- situations.
`
`23· · · · · ·MR. GERGELY:· Okay.· Thanks.
`
`24· · · · · ·THE WITNESS:· They have my copy of this
`
`25· document, so...
`
`
`U.S. LEGAL SUPPORTU.S. LEGAL SUPPORT
`
`(415) 362-4346(415) 362-4346
`
`CFAD v. Anacor, IPR2015-01776
`ANACOR EX. 2033 - 24/583
`
`YVer1f
`
`Page 24
`
`Anacor Exhibit 2010
`Flatwing Pharmaceuticals, Inc. v. Anacor Pharmaceuticals, Inc
`IPR2018-00171
`
`
`
`
`Stephen B. Kahl, Ph.D.Stephen B. Kahl, Ph.D.
`
`April 07, 2016April 07, 2016
`
`25
`
`·1· · · · · ·(Patent Owners' Exhibit 1006 was marked
`
`·2· · · · · ·for identification.)
`
`·3· BY MR. BERMAN:
`
`·4· · · ·Q· ·Dr. Kahl, is this your declaration in support of
`
`·5· the petition for inter partes review of Patent No. '621,
`
`·6· patent in IPR2015-01776?
`
`·7· · · ·A· ·It appears to be.
`
`·8· · · ·Q· ·Do you have any corrections or changes that you
`
`·9· would like to make to this declaration?
`
`10· · · ·A· ·No.
`
`11· · · ·Q· ·Would you please turn to paragraph 13 of
`
`12· Exhibit 1006, please?
`
`13· · · ·A· ·Uh-huh.
`
`14· · · ·Q· ·Paragraph 13 states, "I reviewed the following
`
`15· documents and information," and then provides a list,
`
`16· correct?
`
`17· · · ·A· ·Correct.
`
`18· · · ·Q· ·In preparing your declaration, did you review
`
`19· any other documents than those provided in -- than those
`
`20· identified in paragraph 13?
`
`21· · · ·A· ·I don't believe so.
`
`22· · · ·Q· ·So that's, no, you didn't?
`
`23· · · ·A· ·I don't believe that I did.
`
`24· · · ·Q· ·Is there some uncertainty?
`
`25· · · ·A· ·I have a list here that I recognize.
`
`
`U.S. LEGAL SUPPORTU.S. LEGAL SUPPORT
`
`(415) 362-4346(415) 362-4346
`
`CFAD v. Anacor, IPR2015-01776
`ANACOR EX. 2033 - 25/583
`
`YVer1f
`
`Page 25
`
`Anacor Exhibit 2010
`Flatwing Pharmaceuticals, Inc. v. Anacor Pharmaceuticals, Inc
`IPR2018-00171
`
`
`
`
`Stephen B. Kahl, Ph.D.Stephen B. Kahl, Ph.D.
`
`April 07, 2016April 07, 2016
`
`26
`
`·1· · · · · ·I'm not aware that there's anything missing from
`
`·2· the list.
`
`·3· · · ·Q· ·And, Dr. Kahl, in preparing this declaratio
Accessing this document will incur an additional charge of $.
After purchase, you can access this document again without charge.
Accept $ Charge
Still Working On It
This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.
Give it another minute or two to complete, and then try the refresh button.
A few More Minutes ... Still Working
It can take up to 5 minutes for us to download a document if the court servers are running slowly.
Thank you for your continued patience.
This document could not be displayed.
We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.
Your account does not support viewing this document.
You need a Paid Account to view this document. Click here to change your account type.
Your account does not support viewing this document.
Set your membership
status to view this document.
With a Docket Alarm membership, you'll
get a whole lot more, including:
- Up-to-date information for this case.
- Email alerts whenever there is an update.
- Full text search for other cases.
- Get email alerts whenever a new case matches your search.
One Moment Please
The filing “” is large (MB) and is being downloaded.
Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.
Your document is on its way!
If you do not receive the document in five minutes, contact support at support@docketalarm.com.
Sealed Document
We are unable to display this document, it may be under a court ordered seal.
If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.
Access Government Site
